Monday, the Israeli Occupation and New Zealand have given temporary approval for the sale of a nasal spray from SaNOtize Research and Development’s Nitric Oxide Nasal Spray (NONS) which could help prevent coronavirus transmission.

It is expected to be on sale in the Israeli Occupation and New Zealand there this summer.

In New Zealand, SaNOtize registered its nasal spray with the New Zealand Medicines and Medical Devices Safety Authority, which permits the company to distribute and sell them over the counter immediately.

The spray protects those who use it from viruses that enter the body through the upper nasal pathways.

Moreover, the company last week, in coordination with Ashford and St Peter’s Hospitals NHS Foundation Trust in the UK, announced results of clinical trials showing that the spray was effective in preventing COVID-19 transmissions, shorten its infection course, and reduces the severity of symptoms in already infected patients.

SaNOtize's Chief Science Officer, Chris Miller, said the spray is designed to “kill viruses in the upper airways, preventing them from incubating and spreading to the lungs.”